Alli Articles
EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri
20 February 2012
GlaxoSmithKline to shed OTC brands, including Alli, as US consumer group calls for the latter to be banned
18 April 2011
FDA warns US consumers about counterfeit weight-loss drug Alli
19 January 2010
FDA eyes orlistat for potential liver problems, Chantix under scrutiny for skin reaction
5 June 2009
UK pharmacists alerted on orlistat dispensing
28 April 2009
GSK France welcomes alli launch OK from EC
22 April 2009
Japan stock market week to Jan 19, 2009
26 January 2009
EC approves GSK's OTC orlistat product alli
26 January 2009
EMEA approves GSK's OTC obesity drug
3 November 2008
UPDATE: 2007 NASSO conference hears encouraging data on GSK's alli, Orexigen's Contrave et al
29 October 2007
Under 5% of patients discontinue GSK's alli due to AEs
29 October 2007
GSK's alli goes on sale OTC across the USA
18 June 2007
GSK's orlistat 60mg gets FDA OK for OTC
19 February 2007
HAFSLUND NYCOMED 46% OPERATING PROFIT JUMP
17 February 1992
Showing 1-23 of 23 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
